Outcomes of patients with metastatic non-clear-cell renal cell carcinoma treated with Pazopanib

Matrana, Marc R. , Baiomy, Ali, Campbell, Matthew, Alamri, Suhail, Shetty, Aditya, Teegavarapu, Purnima, Kalra, Sarathi, Xiao, Lianchun, Atkinson, Bradley, Corn, Paul, Jonasch, Eric, Elsayes, Khaled M. and Tannir, Nizar M. (2016) Outcomes of patients with metastatic non-clear-cell renal cell carcinoma treated with Pazopanib. Clinical Genitourinary Cancer, . doi:10.1016/j.clgc.2016.07.016


Author Matrana, Marc R.
Baiomy, Ali
Campbell, Matthew
Alamri, Suhail
Shetty, Aditya
Teegavarapu, Purnima
Kalra, Sarathi
Xiao, Lianchun
Atkinson, Bradley
Corn, Paul
Jonasch, Eric
Elsayes, Khaled M.
Tannir, Nizar M.
Title Outcomes of patients with metastatic non-clear-cell renal cell carcinoma treated with Pazopanib
Journal name Clinical Genitourinary Cancer   Check publisher's open access policy
ISSN 1938-0682
1558-7673
Publication date 2016-06-01
Sub-type Article (original research)
DOI 10.1016/j.clgc.2016.07.016
Open Access Status Not yet assessed
Total pages 4
Place of publication New York, NY, United States
Publisher Elsevier
Collection year 2017
Formatted abstract
Background: Pazopanib is associated with increased progression-free survival (PFS) in clear-cell renal cell carcinoma (RCC) and has become a standard of care in this disease. The drug is used in metastatic non-clear-cell RCC, but data on outcomes in this setting are limited.

Patients and Methods: We conducted a retrospective data analysis of records of consecutive metastatic non-clear-cell RCC patients who received pazopanib in front-line and salvage settings between November 2009 and November 2012. Tumor response rate was assessed by a blinded radiologist using Response Evaluation Criteria in Solid Tumors version 1.1. PFS and overall survival (OS) times were estimated using Kaplan-Meier methods.

Results: Twenty-nine patients were identified with non-clear-cell metastatic RCC, 9 received pazopanib in the front-line setting, 20 in the salvage setting after progression of disease with other targeted therapies. Seven patients (24%) had papillary RCC, 4 (14%) had chromophobe, 5 (17%) had unclassified histopathology, and 13 (45%) had other subtypes including collecting duct, translocation Xp11.2, and various subtypes with sarcomatoid differentiation. All patients discontinued pazopanib before analysis. Median PFS was 8.1 months (95% CI, 5.7-NA [not available]) in the front-line group, and 4 months (95% CI, 2.1-9.9) in the salvage group. Median OS was 31 months (95% CI, 9.2-NA) in the front-line group, and 13.6 months (95% CI, 6.4-NA) in the salvage group.

Conclusion: Pazopanib showed efficacy in patients with metastatic non-clear-cell RCC in the front-line and salvage settings. Toxicity was mild to moderate and manageable. Further studies are needed to evaluate pazopanib's role in non-clear-cell RCC in terms of efficacy and safety.
Keyword Angiogenesis
Kidney cancer
Late relapse
MTOR inhibitor
Targeted therapy
Tyrosine-kinase inhibitor
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Wed, 29 Mar 2017, 13:24:02 EST by Anthony Yeates on behalf of Learning and Research Services (UQ Library)